Posatex Otic Suspension, 15 gm treats otitis externa in dogs caused by yeast or bacteria. This dog ear medicine is anti-inflammatory and reduce ear pain in dogs as well as ear infection in dogs.
It also has antibacterial and antifungal properties.
Each gram of this ear cleaner for dog contains 10 mg of orbifloxacin; mometasone furoate monohydrate equivalent to 1 mg mometasone furoate; and 1 mg of posaconazole in a mineral oil based system containing a plasticized hydrocarbon gel.
Posatex by INTERVET INC., is simple to use with once-daily dosing.
Four drops of this pet ear cleaner delivers approximately 1.0 mg orbifloxacin, 0.1 mg of mometasone furoate monohydrate, and 0.1 mg of posaconazole.
You can order the Posatex Otic Suspension, 15 gm, dog ear medicine and other prescription drugs for pets from pet drugs online. At our Texas based pet pharmacy online, we offer highest quality pet prescription medication for your beloved pet.
Otic Use in Dogs Only
Federal law restricts this pet medicine to use by or on the order of a licensed veterinarian.
Federal law prohibits the extra label use of this drug in food-producing animals.
- Treats otitis externa in dog
- Treats inflammation in ear canals of your dog
- Anti-bacterial, anti-fungal, anti-inflammatory ear cleanser for dog
- Dries out moist environments where bacteria and yeast can thrive
POSATEX™ Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis).
DOSAGE AND ADMINISTRATION:
Shake well before use. For dogs weighing less than 30 lbs. instill 4 drops of this dog ear drops once daily into the ear canal of your dog. For dogs weighing 30 lbs. or more, instill 8 drops of this dog ear medicine once daily into the ear canal. Therapy should continue for 7 consecutive days.
POSATEX™ Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to quinolones, mometasone furoate monohydrate, or posaconazole. Do not use this pet ear cleaner in dogs with known tympanic perforation.
This pet medicine is not for use in humans. Keep this pet ear cleaner out of reach of children.
Do not administer orally. Immediately discontinue use of dog ear drops if hearing loss is observed during treatment with this pet ear cleaner.
The use of this dog ear medicine in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membranes should be confirmed before administering this pet ear cleaner product.
Avoid prolonged or repeated use of dog medication. Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs.
The safe use of POSATEX™ Otic Suspension in dogs used for breeding purposes, during pregnancy or in lactating bitches, has not been evaluated. The systemic administration of quinolones has been shown to produce cartilage erosions of weight bearing joints and other signs of arthropathy in immature animals of various species.
In the field study, 143 dogs were treated with this dog ear medicine. Of those, 1 dog with bilateral otitis externa developed hearing loss. POSATEX™ Otic Suspension treatment was discontinued and the condition resolved in one week.
To report suspected adverse reactions, call 1-800-224-5318.
For a copy of the Material Safety Data Sheet (MSDS) call 1-800-770-8878.
Orbifloxacin is a synthetic fluoroquinolone antibacterial agent. The bactericidal action of fluoroquinolones is concentration-dependent and results from interference with bacterial DNA gyrase and topoisomerase IV. Since these enzymes are needed for bacterial DNA synthesis and transcription, fluoroquinolones disrupt bacterial replication and lead to bacterial cell death.
Mometasone furoate monohydrate is a topical corticosteroid characterized by a (2’) furoate 17-ester having chlorine at the 9 and 21 positions.
Posaconazole is a broad-spectrum triazole antifungal agent. The mechanism by which triazoles exert fungicidal action involves the selective inhibition of the enzyme lanosterol a C14 demethylase (a microsomal cytochrome P-450- dependent enzyme) involved in ergosterol biosynthesis in yeasts and filamentous fungi.
Systemic absorption of the active ingredients was determined in single-dose radiolabelled studies with14C-orbifloxacin, 3H-mometasone furoate, and 14C-posaconazole contained within the ear drops for dogs formulation and placed into the ear canals of normal beagle dogs. Most of the absorption occurred in the first few days of administration. The extent of percutaneous absorption of topical medications is influenced by many factors including the integrity of the epidermal barrier. Inflammation can increase the percutaneous absorption of drugs.
The effectiveness of dog ear cleaner was evaluated in a placebo-controlled, double-blind, multi-site field study. One hundred and ninety one dogs with naturally occurring clinical otitis externa in dogs associated with both yeast and bacteria were randomly allocated to either POSATEX™
Otic Suspension or placebo ointment. Of the 160 dogs evaluated for effectiveness, 122 were treated with POSATEX™ Otic Suspension and 38 were treated with placebo ointment. Treatments were administered once daily for 7 consecutive days. Assessment of effectiveness was based on improvement in clinical signs at re-evaluation 2-7 days following administration of the last dose.
Compared to the placebo, a significant percent of dogs treated with POSATEX™ Otic Suspension showed improvement in clinical signs (discomfort, erythema, and swelling) caused by otitis externa in dogs associated with one or more of the following organisms:
Malassezia pachydermatis, coagulase positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis.
Percent of Dogs Showing Improvement in Clinical Signs of Otitis Externa
|Clinical Sign||POSATEX™ Otic Suspension Group||Placebo Group||Significance|
|External Ear Canal Erythema||81%||39%||p<0.0001|
|External Ear Canal Swelling||83%||49%||p=0.0001|
POSATEX™ Otic Suspension was administered at 1,3, and 5 times the recommended dosage for 21 consecutive days. The control group received the vehicle in both ears at the clinical dose given five times per day. There was a slight decrease in serum cortisol concentration a er ACTH stimulation on Day 21 in the 5X group. Erythema was noted in all groups. Aural pain, swelling, or heat was each noted in 3 separate dogs in the 5X group.
Store this pet ear cleanser at temperatures between 2°-30°C (35.6°-86°F).
Shake well before use.
POSATEX™ Otic Suspension, dog ear medicine is available in 7.5 g, 15